natgillin/translations-raw huggingface dataset:
Mekanismen med hvilken IntronA kan ændre thyreoideafunktionen er ukendt.
The mechanism by which Intron A may alter thyroid status is unknown.
4. 5).
 155 the risk of increased toxicity, careful adjustments of doses are required for IntronA and for the concomitant chemotherapeutic agents (see section 4.5).
156 4. 6 Graviditet og amning
 156 Women of childbearing potential have to use effective contraception during treatment.
157 Tabel 1.
 157 Table 1.
Immunsystemet§
Not known: § Immune system disorders
Almindelig:
Very rarely:
Vertigo, tinnitus
Vertigo, tinnitus Hearing loss, hearing disorder
For eksempel var
 159 The undesirable effects seen with hepatitis C are representative of those reported when IntronA is administered in other indications, with some anticipated dose-related increases in incidence.
159 incidensen af træthed, feber, myalgi, neutropeni/ anæmi, anoreksi, kvalme og opkastning, diarré, kulderystelser, influenzalignende symptomer, depression, alopeci, smagsforstyrrelser og svimmelhed i en undersøgelse af højdosis adjuverende IntronA behandling hos patienter med melanom større end i hepatitis C undersøgelserne.
For example, in a trial of high-dose adjuvant IntronA treatment in patients with melanoma, incidences of fatigue, fever, myalgia, neutropaenia/anaemia, anorexia, nausea and vomiting, diarrhoea, chills, flu- like symptoms, depression, alopecia, altered taste, and dizziness were greater than in the hepatitis C trials.
161 Almene symptomer og reaktioner på administartionsstedet Meget almindelig:
161
Nogle eller alle af disse aktiviteter kan være medvirkende til interferons terapeutiske effekt.
It is thought that this process, at least in part, is responsible for the various cellular responses to interferon, including inhibition of virus replication in virus-infected cells, suppression of cell proliferation and such immunomodulating activities as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells.
Rekombinant interferon alfa- 2b har vist antiproliferative effekter i undersøgelser under anvendelse af både animale og humane cellekultursystemer, såvel som humane tumor xentotransplantater på dyr.
Any or all of these activities may contribute to interferon's therapeutic effects.  162 Recombinant interferon alfa-2b has exhibited antiproliferative effects in studies employing both animal and human cell culture systems as well as human tumour xenografts in animals.
163
 163
164 Tabel 4
 164 Table 4
4. 1, 4. 4 og 4. 8).
 165, the benefit/risk of the combination of ribavirin and interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8).
Tabel 6.
 166 Table 6.
167 6. 4 Særlige opbevaringsforhold
6.4 Special precautions for storage
0, 5 ml opløsning (svarende til 5 MIE) i et hætteglas (type I glas), med en prop (halobutylgummi) i et aftageligt segl (aluminium) med en hætte (polypropylen).
0.5 ml of solution (corresponding to 5 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene).
0, 5 ml opløsning (svarende til 5 MIE) i et hætteglas (type I glas), med en prop (halobutylgummi) i et aftageligt segl (aluminium) med en hætte (polypropylen) med 1 injektionssprøjte, 1 kanyle og 1 renseserviet.
0.5 ml of solution (corresponding to 5 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) with 1 injection syringe, 1 injection needle and 1 cleansing swab.
I lighed med alle parenterale lægemidler undersøges IntronA, injektionsvæske eller infusionsvæske, opløsning visuelt for partikler og misfarvning før brugen.
 168 As with all parenteral medicinal products, prior to administration inspect IntronA, solution for injection or infusion, visually for particulate matter and discolouration.
168 8.
8.
IntronA 10 millioner IE/ ml injektionsvæske eller infusionsvæske, opløsning
IntronA 10 million IU/ml solution for injection or infusion
Et hætteglas IntronA injektionsvæske eller infusionsvæske, opløsning éndosis hætteglas indeholder 10 millioner IE rekombinant interferon alfa- 2b, produceret i E. coli ved rekombinant DNA - teknologi, i 1 ml opløsning.
One vial of IntronA solution for injection or infusion, single dose vial, contains 10 million IU of recombinant interferon alfa-2b produced in E.coli by recombinant DNA technology, in 1 ml of solution.
Kombinationen af interferon alfa- 2b og cytarabin (Ara- C) givet under de første 12 måneders behandling har vist signifikant at øge hyppigheden af større cytogenetisk respons og signifikant at forlænge den samlede overlevelse efter 3 år sammenlignet med interferon alfa- 2b givet alene.
 170 major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.
171 (Se produktresume for ribavirin kapsler med henblik på dosis af ribavirin kapsler og retningslinierne for dosisindstilling ved kombinationsbehandling.
(See ribavirin capsule SPC for dose of ribavirin capsules and dosage modification guidelines for combination therapy.
172 Kronisk myeloid leukæmi:
Chronic Myelogenous Leukaemia:
Nogle patienter har vist at have gavn af IntronA 5 millioner IE/ m2 indgivet dagligt subkutant i forbindelse med cytarabin (Ara- C) 20 mg/ m2 indgivet dagligt subkutant i 10 dage per måned (op til en maksimal daglig dosis på 40 mg).
 172 5 million IU/m2 administered daily subcutaneously in association with cytarabine (Ara-C) 20 mg/m2 administered daily subcutaneously for 10 days per month (up to a maximum daily dose of 40 mg).
173 Børn og unge:
 173
Ætiologien er ikke fastlagt.
The  174 aetiology has not been defined.
175 Alle patienter i de kliniske undersøgelser af kronisk hepatitis C fik foretaget leverbiopsi før inklusion, men i visse tilfælde (for eksempel patienter med genotype 2 og 3), kan behandling være mulig uden histologisk verifikation.
Also see ribavirin SPC if IntronA is to be administered in combination with ribavirin in patients with chronic hepatitis C.
4. 5).
 176 the risk of increased toxicity, careful adjustments of doses are required for IntronA and for the concomitant chemotherapeutic agents (see section 4.5).
177 4. 6 Graviditet og amning
 177 Women of childbearing potential have to use effective contraception during treatment.
178 Tabel 1.
 178 Table 1.
For eksempel var
 180 The undesirable effects seen with hepatitis C are representative of those reported when IntronA is administered in other indications, with some anticipated dose-related increases in incidence.
180 incidensen af træthed, feber, myalgi, neutropeni/ anæmi, anoreksi, kvalme og opkastning, diarré, kulderystelser, influenzalignende symptomer, depression, alopeci, smagsforstyrrelser og svimmelhed i en undersøgelse af højdosis adjuverende IntronA behandling hos patienter med melanom større end i hepatitis C undersøgelserne.
For example, in a trial of high-dose adjuvant IntronA treatment in patients with melanoma, incidences of fatigue, fever, myalgia, neutropaenia/anaemia, anorexia, nausea and vomiting, diarrhoea, chills, flu- like symptoms, depression, alopecia, altered taste, and dizziness were greater than in the hepatitis C trials.
181
 181 Neoplasms benign, malignant and unspecified (including cysts and polyps) Common:
182 Almene symptomer og reaktioner på administartionsstedet Meget almindelig:
182
Rekombinant interferon alfa- 2b har vist antiproliferative effekter i undersøgelser under anvendelse af både animale og humane cellekultursystemer, såvel som humane tumor xentotransplantater på dyr.
Any or all of these activities may contribute to interferon's therapeutic effects.  183 Recombinant interferon alfa-2b has exhibited antiproliferative effects in studies employing both animal and human cell culture systems as well as human tumour xenografts in animals.
184
 184
185 Tabel 4
 185 Table 4
4. 1, 4. 4 og 4. 8).
 186, the benefit/risk of the combination of ribavirin and interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8).
Tabel 6.
 187 Table 6.
188 6. 4 Særlige opbevaringsforhold
6.4 Special precautions for storage
1 ml opløsning (svarende til 10 MIE) i et hætteglas (type I glas), med en prop (halobutylgummi) i et aftageligt segl (aluminium) med en hætte (polypropylen).
1 ml of solution (corresponding to 10 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene).
Pakningsstørrelse á 1, 6 eller 12.
1 ml of solution (corresponding to 10 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) with 1 injection syringe, 1 injection needle and 1 cleansing swab.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Packs sizes of 1, 6 or 12 Not all pack sizes may be marketed.
I lighed med alle parenterale lægemidler undersøges IntronA, injektionsvæske eller infusionsvæske, opløsning visuelt for partikler og misfarvning før brugen.
 189 As with all parenteral medicinal products, prior to administration inspect IntronA, solution for injection or infusion, visually for particulate matter and discolouration.
IntronA 18 millioner IE/ 3 ml injektionsvæske eller infusionsvæske, opløsning
IntronA 18 million IU/3 ml solution for injection or infusion
Et hætteglas IntronA injektionsvæske eller infusionsvæske, opløsning flerdosis hætteglas indeholder 18 millioner IE rekombinant interferon alfa- 2b, produceret i E. coli ved rekombinant DNA - teknologi, i 3 ml opløsning.
One vial of IntronA solution for injection or infusion, multiple dose vial, contains 18 million IU of recombinant interferon alfa-2b produced in E.coli by recombinant DNA technology, in 3 ml of solution.
En ml opløsning indeholder 6 millioner IE interferon alfa- 2b.
One ml of solution contains 6 million IU of interferon alfa-2b.
191 leukæmiske celler i knoglemarven, mens et mindre respons er  34%, men < 90% Ph+ celler i marven.
A major cytogenetic response is defined by < 34% Ph+ leukaemic cells in the bone marrow, whereas a minor response is  34%, but < 90% Ph+ cells in the marrow.
Kombinationsbehandling:
 191 Combination therapy:
192 (Se produktresume for ribavirin kapsler med henblik på dosis af ribavirin kapsler og retningslinierne for dosisindstilling ved kombinationsbehandling.
 192 (See ribavirin capsule SPC for dose of ribavirin capsules and dosage modification guidelines for combination therapy.
193 Kronisk myeloid leukæmi:
 193 Chronic Myelogenous Leukaemia:
194 Børn og unge:
 194 Children and adolescents:
Lungeinfiltrat, pneumonitis og pneumonia, undertiden resulterende i dødsfald, er sjældent blevet observeret hos interferon- alfa behandlede patienter, inklusive de, som er behandlet med IntronA.
 195 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
Kronisk hepatitis C:
 196 Chronic Hepatitis C:
196 Alle patienter i de kliniske undersøgelser af kronisk hepatitis C fik foretaget leverbiopsi før inklusion, men i visse tilfælde (for eksempel patienter med genotype 2 og 3), kan behandling være mulig uden histologisk verifikation.
All patients in the chronic hepatitis C studies had a liver biopsy before inclusion, but in certain cases (i.e. patients with genotype 2 and 3), treatment may be possible without histological confirmation.
De mest almindeligt rapporterede potentielle livstruende eller fatale bivirkninger inkluderer mucositis, diarré, neutropeni, nyreinsufficiens og elektrolytforstyrrelse.
The most commonly reported potentially life-threatening or fatal adverse events
198 4. 6 Graviditet og amning
 198 Women of childbearing potential have to use effective contraception during treatment.
199 Tabel 1.
Table 1.
Sjælden:
 199 Very rarely:
Tab af hørelse, høreforstyrrelser
Vertigo, tinnitus Hearing loss, hearing disorder
For eksempel var
The undesirable effects seen with hepatitis C are representative of those reported when IntronA is administered in other indications, with some anticipated dose-related increases in incidence.
201 incidensen af træthed, feber, myalgi, neutropeni/ anæmi, anoreksi, kvalme og opkastning, diarré, kulderystelser, influenzalignende symptomer, depression, alopeci, smagsforstyrrelser og svimmelhed i en undersøgelse af højdosis adjuverende IntronA behandling hos patienter med melanom større end i hepatitis C undersøgelserne.
For example, in a trial of high-dose adjuvant IntronA treatment in patients with melanoma, incidences of fatigue, fever, myalgia, neutropaenia/anaemia, anorexia, nausea and vomiting, diarrhoea, chills, flu- like symptoms, depression, alopecia, altered taste, and dizziness were greater than in the hepatitis C trials.
4. 4).
 201 that may be reversible upon discontinuation of interferon alpha, has been reported rarely in patients without prior evidence of cardiac disease (see section 4.4).
203 Almene symptomer og reaktioner på administartionsstedet Meget almindelig:
Very common:
4. 9 Overdosering
 203 4.9 Overdose
204 inklusiv hæmning af virusreplikation i virusinficerede celler, suppression af celledeling og sådanne immunmodulerende aktiviteter som øgning af den fagocytære aktivitet af makrofager og øgning af den specifikke cytotoksicitet af lymfocytter på målcellerne.
It is thought that this process, at least in part, is responsible for the various cellular responses to interferon, including inhibition of virus replication in virus-infected cells, suppression of cell proliferation and such immunomodulating activities as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells.
Nuværende kliniske erfaringer med patienter, som forbliver i interferon alfa- 2b behandling i 4 til 6 måneder, viser, at behandlingen kan give elimination af serum HBV- DNA.
 204 Current clinical experience in patients who remain on interferon alfa-2b for 4 to 6 months indicates that therapy can produce clearance of serum HBV-DNA.
205
 205
Patienterne blev randomiseret til enten at få pegyleret interferon alfa 2b (1, 5 µg/ kg/ uge) plus ribavirin (800 mg/ dag) eller IntronA (3 MIE TIW) plus ribavirin (800 mg/ dag) i 48 uger med en opfølgningsperiode på 6 måneder.
Patients were randomized to receive either pegylated interferon alfa-2b (1.5 µg/kg/ week) plus ribavirin (800 mg/day) or IntronA (3 MIU TIW) plus ribavirin (800 mg/day) for 48 weeks with a follow-up period of 6 months.
206 Tabel 4
 206 Table 4
6% (8/ 129)
1,200 mg)
4. 1, 4. 4 og 4. 8).
 207, the benefit/risk of the combination of ribavirin and interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8).
Tabel 6.
 208 Table 6.
Efter første anvendelse:
After first opening the container:
Fysisk- kemisk stabilitet under brug er vist i 28 dage ved 2C - 8C.
Chemical and physical in-use stability has been demonstrated for 28 days at 2ºC – 8ºC.
Fra et mikrobiologisk synspunkt kan produktet når det er åbnet opbevares i maksimalt 28 dage ved 2C - 8C.
From a microbiological point of view, once opened, the product may be stored for a maximum of 28 days at 2ºC – 8ºC.
209 Opbevares i køleskab (2°C - 8°C).
Store in a refrigerator (2°C – 8°C).
3 ml opløsning (svarende til 18 MIE) i et hætteglas (type I glas), med en prop (halobutylgummi) i et aftageligt segl (aluminium) med en hætte (polypropylen).
3 ml of solution (corresponding to 18 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene).
Pakningsstørrelse á 1, 2 eller 12.
3 ml of solution (corresponding to 18 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) with 6 injection syringes, 6 injection needles and 12 cleansing swabs.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Pack sizes of 1, 2 or 12 Not all pack sizes may be marketed.
Enhver størrelse hætteglas kan anvendes til at måle den nødvendige dosis, men slutkoncentrationen af interferon i natriumchloridopløsning må ikke være mindre end 0, 3 millioner IE/ ml.
The appropriate dose of
Den beregnede mængde IntronA trækkes op af hætteglasset (glassene), tilsættes til 50 ml 9 mg/ ml (0, 9%) natriumchlorid injektionsvæske, opløsning i en PVC pose eller glasflaske til infusionsbrug og indgives over 20 minutter
 210 IntronA is withdrawn from the vial(s), added to 50 ml of 9 mg/ml (0.9%) sodium chloride solution for injection in a PVC bag or glass bottle for intravenous use and administered over 20 minutes.
I lighed med alle parenterale lægemidler undersøges IntronA, injektionsvæske eller infusionsvæske, opløsning visuelt for partikler og misfarvning før brugen.
As with all parenteral medicinal products, prior to administration inspect IntronA, solution for injection or infusion, visually for particulate matter and discolouration.
210 8.
8.
IntronA 25 millioner IE/ 2, 5 ml injektionsvæske eller infusionsvæske, opløsning
IntronA 25 million IU/2.5 ml solution for injection or infusion
Et hætteglas IntronA injektionsvæske eller infusionsvæske, opløsning flerdosis hætteglas indeholder 25 millioner IE rekombinant interferon alfa- 2b, produceret i E. coli ved rekombinant DNA - teknologi, i 2, 5 ml opløsning.
One vial of IntronA solution for injection or infusion, multiple dose vial, contains 25 million IU of recombinant interferon alfa-2b produced in E.coli by recombinant DNA technology, in 2.5 ml of solution.
En ml opløsning indeholder 10 millioner IE interferon alfa- 2b.
One ml of solution contains 10 million IU of interferon alfa-2b.
212 leukæmiske celler i knoglemarven, mens et mindre respons er  34%, men < 90% Ph+ celler i marven.
A major cytogenetic response is defined by < 34% Ph+ leukaemic cells in the bone marrow, whereas a minor response is  34%, but < 90% Ph+ cells in the marrow.
Kombinationsbehandling:
 212 Combination therapy:
213 (Se produktresume for ribavirin kapsler med henblik på dosis af ribavirin kapsler og retningslinierne for dosisindstilling ved kombinationsbehandling.
 213 (See ribavirin capsule SPC for dose of ribavirin capsules and dosage modification guidelines for combination therapy.
214 Kronisk myeloid leukæmi:
 214 Chronic Myelogenous Leukaemia:
215 Børn og unge:
 215 Children and adolescents:
Lungeinfiltrat, pneumonitis og pneumonia, undertiden resulterende i dødsfald, er sjældent blevet observeret hos interferon- alfa behandlede patienter, inklusive de, som er behandlet med IntronA.
 216 Pulmonary infiltrates, pneumonitis, and pneumonia, occasionally resulting in fatality, have been observed rarely in interferon alpha treated patients, including those treated with IntronA.
Kronisk hepatitis C:
 217 Chronic Hepatitis C:
217 Alle patienter i de kliniske undersøgelser af kronisk hepatitis C fik foretaget leverbiopsi før inklusion, men i visse tilfælde (for eksempel patienter med genotype 2 og 3), kan behandling være mulig uden histologisk verifikation.
All patients in the chronic hepatitis C studies had a liver biopsy before inclusion, but in certain cases (i.e. patients with genotype 2 and 3), treatment may be possible without histological confirmation.
219 4. 6 Graviditet og amning
 219 Women of childbearing potential have to use effective contraception during treatment.
220 Tabel 1.
Table 1.
Sjælden:
 220 Very rarely:
Inflammation på injektionsstedet, reaktion på injektionsstedet *, træthed, stivhed, feber§, influenzalignende
Injection site inflammation, injection site reaction*, fatigue, rigors, fever§, flu-like symptoms§, asthenia, irritability, chest pain, malaise
symptomer§, asteni, irritabilitet, brystsmerte, utilpashed Smerte på injektionsstedet Nekrose på injektionsstedet, ansigtsødem
Injection site pain Injection site necrosis, face oedema
222 incidensen af træthed, feber, myalgi, neutropeni/ anæmi, anoreksi, kvalme og opkastning, diarré, kulderystelser, influenzalignende symptomer, depression, alopeci, smagsforstyrrelser og svimmelhed i en undersøgelse af højdosis adjuverende IntronA behandling hos patienter med melanom større end i hepatitis C undersøgelserne.
For example, in a trial of high-dose adjuvant IntronA treatment in patients with melanoma, incidences of fatigue, fever, myalgia, neutropaenia/anaemia, anorexia, nausea and vomiting, diarrhoea, chills, flu- like symptoms, depression, alopecia, altered taste, and dizziness were greater than in the hepatitis C trials.
4. 4).
 222 that may be reversible upon discontinuation of interferon alpha, has been reported rarely in patients without prior evidence of cardiac disease (see section 4.4).
224 Almene symptomer og reaktioner på administartionsstedet Meget almindelig:
Very common:
4. 9 Overdosering
 224 4.9 Overdose
225 inklusiv hæmning af virusreplikation i virusinficerede celler, suppression af celledeling og sådanne immunmodulerende aktiviteter som øgning af den fagocytære aktivitet af makrofager og øgning af den specifikke cytotoksicitet af lymfocytter på målcellerne.
It is thought that this process, at least in part, is responsible for the various cellular responses to interferon, including inhibition of virus replication in virus-infected cells, suppression of cell proliferation and such immunomodulating activities as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells.
Nuværende kliniske erfaringer med patienter, som forbliver i interferon alfa- 2b behandling i 4 til 6 måneder, viser, at behandlingen kan give elimination af serum HBV- DNA.
 225 Current clinical experience in patients who remain on interferon alfa-2b for 4 to 6 months indicates that therapy can produce clearance of serum HBV-DNA.
226
 226
227 Tabel 4
 227 Table 4
Vedvarende virologisk respons baseret på genotype efter IntronA i kombination med ribavirin versus pegyleret interferon alfa- 2b i kombination med ribavirin hos patienter med samtidig infektion af HCV/ HIV Undersøgelse 11 Undersøgelse 22 pegyleret pegyleret interferon interferon alfa- 2b (100 alfa- 2b eller IntronA (1, 5 µg/ kg / IntronA 150c µg/ uge) (3 MIE TIW) uge) + (3 MIE TIW) + + ribavirin + ribavirin ribavirin ribavirin p (800 - (800 - p (800 mg) (800 mg) værdi a 1. 200 mg) d 1. 200 mg) d værdib
Sustained virological res ponse based on genotype ribavirin versus pegylated interferon alfa-2b in HCV/HIV co-infected patients
4. 1, 4. 4 og 4. 8).
 228, the benefit/risk of the combination of ribavirin and interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8).
Tabel 6.
 229 Table 6.
6. 4 Særlige opbevaringsforhold 230 Opbevares i køleskab (2°C - 8°C).
6.4 Special precautions for storage
2, 5 ml opløsning (svarende til 25 MIE) i et hætteglas (type I glas), med en prop (halobutylgummi) i et aftageligt segl (aluminium) med en hætte (polypropylen).
2.5 ml of solution (corresponding to 25 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene).
Pakningsstørrelse á 1, 2 eller 12.
2.5 ml of solution (corresponding to 25 MIU) in a vial (type I glass), with a stopper (halobutyl rubber) in a flip-off seal (aluminium) with a bonnet (polypropylene) with 6 injection syringes, 6 injection needles and 12 cleansing swabs.
Den beregnede mængde IntronA trækkes op af hætteglasset (glassene), tilsættes til 50 ml 9 mg/ ml (0, 9%) natriumchlorid injektionsvæske, opløsning i en PVC pose eller glasflaske til infusionsbrug og indgives over 20 minutter
 231 IntronA is withdrawn from the vial(s), added to 50 ml of 9 mg/ml (0.9%) sodium chloride solution for injection in a PVC bag or glass bottle for intravenous use and administered over 20 minutes.
IntronA 18 millioner IE injektionsvæske, opløsning, flerdosispen
IntronA 18 million IU solution for injection, multidose pen
En cylinderampul indeholder 18 millioner IE rekombinant interferon alfa- 2b, produceret i E. coli ved rekombinant DNA- teknologi, i 1, 2 ml.
One cartridge contains 18 million IU of recombinant interferon alfa-2b produced in E.coli by recombinant DNA technology, in 1.2 ml.